Keep trying

Article Abstract:

Hoechst may acquire a majority holding in Marion Merrell Dow (MMD), a pharmaceuticals producer from the US which is controlled by Dow Chemical. THe US accounts for some 6% of Hoechst's turnover, and the company acquired a controlling stake in Copley in 1993. Copley faces allegations over its manufacturing practices which could lead to large liabilities for Hoechst, and this may affect the negotiations to acquire MMD. Neither Hoechst nor Dow Chemical would comment on the negotiations.

Management, Hoechst Marion Roussel Inc., Hoechst AG

---

Norwegians in a spin

Article Abstract:

Hafslund Nycomed is a Norwegian pharmaceuticals concern which plans a demerger. The company plans to split into Nycomed which will take on medical imaging and pharmaceuticals, and Hafslund, which will be involved in hydroelectric power production and distribution. The scheme, which is to be presented to shareholders in May 1996, has not been well received by analysts, and follows a failed merger with Ivax, a US company, which shareholders rejected.

Electric services, Hydroelectric Power, Hydroelectric Power Generation, Hydroelectric power plants, Hafslund Nycomed A/S

---

Glaxo mega-bid born of desperation not innovation: add together two drug companies with growth problems, and you don't necessarily end up with a world-beater. Glaxo's cost-led bid for Wellcome suggests a shortage of ideas at the UK's leading pharmaceuticals grou

Article Abstract:

Glaxo's bid for Wellcome is aimed at reducing the combined overhead of 5.7 billion pounds sterling. The Wellcome Trust, owner of 39.5% of Wellcome PLC, has aggred to sell to Glaxo, but the Charity Commissioners may block the sale. The sale must also have the approval of the High Court. Glaxo would restructure the combined business which could cost 1 billion pounds sterling.

Wellcome PLC, Glaxo

Similar abstracts:

• Abstracts: Predicting stock returns using financial statement information. The long-term price-earnings ratio
• Abstracts: Keeping the high ground. An unusual ambition. Easy when you know how
• Abstracts: Pockets of insider buying. Insiders looking great but.... The state of the tides
• Abstracts: K-III on the prowl again: firm leads pack in scramble for Hunter. Publisher profits driving up prices
• Abstracts: Philip Morris. Marston, Thompson and Evershed: a costly tune. Eldridge Pope's opening time looks overdue

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.